文献速递急性肾损伤慢性肾脏病

YB-1调控CXCL1表达影响肝纤维化中的肾损伤

The nucleic acid binding protein YB-1-controlled expression of CXCL-1 modulates kidney damage in liver fibrosis.
PubMed 文献 · Kidney Int · 2019-11-09

在胆管结扎肝纤维化小鼠模型中,YB-1单倍体不足(Yb1+/-)小鼠肝脏损伤和I型胶原表达显著减轻,但CXCL1表达显著升高。YB-1被鉴定为Cxcl1基因的强效转录抑制因子,Yb1+/-小鼠肾脏CXCR2表达升高且对CXCL1反应增强,导致胆管结扎后肾小管上皮损伤和免疫细胞浸润加重。药理学阻断CXCR2或使用抗CXCL1抗体可显著减轻早期肾脏系统性影响,而对肝脏炎症和功能影响有限。

要点

  • YB-1是Cxcl1基因的转录抑制因子,Yb1+/-小鼠CXCL1表达升高。
  • Yb1+/-小鼠肝纤维化减轻但胆管结扎后肾损伤加重。
  • 阻断CXCR2或CXCL1可减轻肾损伤,对肝脏影响有限。

核心结论

  • YB-1通过维持对趋化因子CXCL1表达的严密控制,促进肝纤维化并调节肝-肾交互作用。

研究设计与样本

  • 在胆管结扎肝纤维化模型中,比较Yb1+/-小鼠与野生型同窝小鼠的肝脏和肾脏损伤。

主要发现

  • Yb1+/-小鼠胆管结扎后血清肝酶水平和肝脏I型胶原等细胞外基质成分表达较野生型显著降低。
  • Yb1+/-小鼠CXCL1表达显著升高,YB-1被鉴定为Cxcl1基因的强效转录抑制因子。
  • Yb1+/-小鼠精密切割肾切片中CXCL1受体CXCR2表达更高,对CXCL1反应性增强。
  • Yb1+/-小鼠CXCL1含量增加导致胆管结扎诱导的肾小管上皮损伤和免疫细胞浸润加重。
  • 药理学阻断CXCR2或应用抗CXCL1抗体显著减轻胆管结扎后早期肾脏系统性影响,对肝脏炎症和功能影响有限。

临床怎么用

  • 靶向CXCL1-CXCR2轴可能减轻晚期肝病相关急性肾损伤,但需进一步临床验证。

局限性

  • 研究基于胆管结扎小鼠模型,结果能否外推至人类肝纤维化相关肾损伤尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute kidney injury is a common complication of advanced liver disease and increased mortality of these patients. Here, we analyzed the role of Y-box protein-1 (YB-1), a nucleic acid binding protein, in the bile duct ligation model of liver fibrosis and monitored liver and subsequent kidney damage. Following bile duct ligation, both serum levels of liver enzymes and expression of hepatic extracellular matrix components such as type I collagen were significantly reduced in mice with half-maximal YB-1 expression (Yb1+/-) as compared to their wild-type littermates. By contrast, expression of the chemokine CXCL1 was significantly augmented in these Yb1+/- mice. YB-1 was identified as a potent transcriptional repressor of the Cxcl1 gene. Precision-cut kidney slices from Yb1+/- mice revealed higher expression of the CXCL1 receptor CXCR2 as well as enhanced responsivity to CXCL1 compared to those from wild-type mice. Increased CXCL1 content in Yb1+/- mice led to pronounced bile duct ligation-induced damage of the kidneys monitored as parameters of tubular epithelial injury and immune cell infiltration. Pharmacological blockade of CXCR2 as well as application of an inhibitory anti-CXCL1 antibody significantly mitigated early systemic effects on the kidneys following bile duct ligation whereas it had only a modest impact on hepatic inflammation and function. Thus, our analyses provide direct evidence that YB-1 crucially contributes to hepatic fibrosis and modulates liver-kidney crosstalk by maintaining tight control over chemokine CXCL1 expression.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Hermert D, Martin IV, Reiss LK, et al. The nucleic acid binding protein YB-1-controlled expression of CXCL-1 modulates kidney damage in liver fibrosis. Kidney Int. 2019. PMID: 32061437. doi:10.1016/j.kint.2019.10.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。